Yi Wang, Jianfen Xu, Mingjun Dong, Kaitai Liu, Yi Lu, Ke Chen, Yuepeng Cao, Hang Shi, Yanping Bei, Jianjiong Li, Jianpei Zhao, Yisheng Cao, Ning Lu, Lu Yang, Haizhong Liu, Ping Cai, Kai Li, Tong Yang, Ning He, Jing Dong, Chen Zhang
BACKGROUND: Randomized trials have shown a survival benefit for fruquintinib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies, but real-world prognostic analyses have been seldom reported. We evaluated survival, safety outcomes, and predictive and prognostic factors in patients treated with fruquintinib in a real-life setting. METHODS: We conducted a multi-center study by collecting relevant data on patients with advanced colorectal cancer (CRC) who received fruquintinib, focusing on progression-free survival (PFS), overall survival (OS), and L3 skeletal muscle index (SMI), including safety follow-up...
August 31, 2024: Journal of Gastrointestinal Oncology